New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 26, 2012
05:55 EDTAMD, AMD, AMD, AMD, AMD, VAR, VAR, VAR, VAR, VAR, RDNT, RDNT, RDNT, RDNT, RDNT, PKI, PKI, PKI, PKI, PKI, NTAP, NTAP, NTAP, NTAP, NTAP, MDT, MDT, MDT, MDT, MDT, HOLX, HOLX, HOLX, HOLX, HOLX, EMC, EMC, EMC, EMC, EMC, DELL, DELL, DELL, DELL, DELL, CERN, CERN, CERN, CERN, CERN, AWRE, AWRE, AWRE, AWRE, AWRE, ATHN, ATHN, ATHN, ATHN, ATHN, T, T, T, T, T, VMW, VMW, VMW, VMW, VMWRadiological Society of North America hosts a conference
RSNA 2012 is being held in Chicago on November 25-30.
News For AMD;T;ATHN;AWRE;CERN;DELL;EMC;HOLX;MDT;NTAP;PKI;RDNT;VAR;VMW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
March 18, 2015
13:59 EDTTT-Mobile announces 'Un-contract,' 'Carrier Freedom' initiatives
Today, during an event held to announce Un-carrier 9.0 − Un-carrier for Business − T-Mobile (TMUS) unveiled two new major Un-carrier initiatives for consumers. First, with T-Mobile’s new "Un-contract," customers will now have more certainty in their wireless pricing than ever before. Consumers and businesses with the Simple Choice rate plan will find that rates won’t go up as long as they’re a T-Mobile customer and keep their plan − and even customers with unlimited 4G LTE will lock in their rates for a minimum of two years. The Un-carrier also launched "Carrier Freedom," a new move where T-Mobile will now cover all outstanding phone and tablet payments up to $650 per line when customers from AT&T (T), Verizon (VZ) or Sprint (S) switch to T-Mobile.
09:33 EDTCERNCerner selected by Washington hospitals to update health record systems
The State of Washington Department of Social and Health Services has selected health IT supplier Cerner to modernize integrated revenue cycle and electronic health records in multiple state facilities to prepare for ICD-10 compliance. The agreement will digitize DSHS' paper health records. Cerner will implement Millennium PowerChart and the revenue cycle suite of solutions at three accredited psychiatric hospitals, including Western State Hospital, Eastern State Hospital and Child Studies and Treatment Center. Cerner will replace the billing functionality supported by the Residential Programs System, as well as the central pharmacy system. DSHS' system will be hosted at Cerner's Kansas City data center.
07:49 EDTEMCSenate Judiciary Committee to hold a hearing
Subscribe for More Information
07:30 EDTTAT&T-DirecTV getting less attention than Comcast-Time Warner Cable, Reuters says
Subscribe for More Information
07:30 EDTRDNTDeutsche Bank to hold a conference
Subscribe for More Information
06:16 EDTTAmerican Express to launch Plenti loyalty program this spring, WSJ reports
Subscribe for More Information
05:39 EDTMDTSt. Jude Medical downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded St. Jude Medical (STJ) to Market Perform saying competitive pressures will drive 2015 market share losses in the company's cardiac rhythm management business, which represents 50% of total sales. Wells believes the launch of CardioMEMS will not be strong enough to offset the headwinds in CRM unit. The firm thinks Boston Scientific's (BSX) earlier than expected approval for its next generation subcutaneous implantable cardioverter-defibrillator called Emblem will drive share gains against St. Jude and Medtronic (MDT) in the single chamber ICD market. Wells cut its price target range for St. Jude shares to $69-$70 from $73-$74. The medical technology company closed yesterday down $2.01 to $65.45.
March 17, 2015
14:55 EDTVMWVMware to face more competitive process for DOD contract, says Stifel
After government websites indicated that Citrix (CTXS), Amazon (AMZN) and others succeeded in getting the DoD to reconsider its awarding of a $1.6B, five-year contract to VMware (VMW), Stifel said it doesn't think VMware has necessarily lost the opportunity, but that the company will now likely face a more competitive bidding process to win the deal. The firm view this example as supporting its concerns that VMware's steps to become a more strategic vendor have the potential to be as much of a threat as an opportunity and Stifel maintains its Hold rating on the stock.
14:43 EDTVMWVMware award from DISA canceled after protest, siliconANGLE reports
On March 12, the Defense Information Security Agency, or DISA, reversed a decision to award VMware (VMW) with a $1.6B contract following protests by Amazon Web Services (AMZN), Citrix Systems (CTXS), and others, reported siliconANGLE. A government posting noted that "Amendment 0002 is issued to cancel the request for proposal to further analyze the government's needs." Reference Link
08:08 EDTVARVarian Medical to create operating entity in Algeria
Subscribe for More Information
07:12 EDTVMWDeutsche Messe to hold a conference
CeBIT 2015 is being held in Hannover, Germany on March 15-20.
March 16, 2015
13:16 EDTMDTAnalysts upbeat on results of Edwards' Sapien 3 data
The shares of Edwards Lifesciences (EW) are rising after the company released data on its Sapien 3 transcathter aortic valve over the weekend. In notes to investors today, a number of analysts were upbeat on the data. BACKGROUND: Edwards yesterday announced that high- and intermediate-risk patients treated with Sapien 3 demonstrated lower mortality rates than patients treated with previous transcathter aortic valves, or TAVR, made by the company. The patients also had excellent clinical outcomes in the other primary endpoints of stroke and paravalvular regurgitation, the company stated. Meanwhile, a five year study of patients treated with the first generation SAPIEN device showed that the patients had equivalent outcomes to traditional open-heart surgery, and no structural valve deterioration requiring intervention, the company stated. ANALYST REACTION: Edwards' Sapien 3 data was impressive, as the device showed one of the lowest stroke and mortality rates of any major TAVR study so far, Bernstein analyst Derrick Sung wrote in a note to investors earlier today. Data presented by Edwards and other companies at the American College of Cardiology, or ACC, conference this weekend caused investors and the medical community to become more optimistic about the potential for TAVR devices to replace surgical valves, Sung stated. The analyst wrote that he continues to believe that investors are underestimating the potential size of the TAVR market. Also upbeat on Edwards' data was Wells Fargo, which wrote that the data exceeded high expectations and could pressure the FDA to approve Sapien 3 for intermediate risk patients earlier than Edwards' guidance of late 2016. WHAT'S NOTABLE: Analysts were also upbeat on data reported by other companies at the ACC conference. Medtronic's (MDT) data suggested that its CoreValve Evolut-R product may be as effective as Edwards' Sapien 3, Bernstein's Sung stated. The FDA appears to have allowed Boston Scientific's (BSX) left atrial appendage closure, Watchman, to be provided to more patients than expected, research firm Stifel believes. Meanwhile, St. Jude's (STJ) CardioMEMS device yielded "impressive" mortality data, the firm added. Stifel kept Buy ratings on both Medtronic and St. Jude. PRICE ACTION: In early afternoon trading, Edwards Lifesciences climbed 9% to $147.64, Boston Scientific advanced 4% to $17.27, St. Jude added 2% to $67.55, and Medtronic rose 1.3% to $77.50.
07:30 EDTMDTAmerican College of Cardiology to hold an expo
Subscribe for More Information
07:22 EDTMDTMedtronic Edwards Lifesciences data 'impressive,' says Bernstein
Subscribe for More Information
06:04 EDTRDNTRadNet 'optimistic' about 2015 although it expects a soft Q1
RadNet commented, "We have significant growth drivers in our plan, including benefiting from capitation contracts we signed in late 2014, revenue from our recently announced breast disease management program in the nation of Qatar and continuing confidence about our ability to drive same-center procedural volumes. Our refinancing transaction in March of last year will result in lower cash interest expense for 2015 and our Capital Expenditures will be lower in 2015 than in 2014. The combination of the lower cash interest expense and capital expenditures will increase our Free Cash Flow in 2015... Our guidance also incorporates what we are projecting to be a soft first quarter in 2015 due to the severe winter weather conditions that have existed in the northeastern and mid-Atlantic parts of the United States throughout January, February and into March of this year."
06:03 EDTRDNTRadNet sees FY15 revenue $745M-$765M, consensus $746.05M
Subscribe for More Information
06:02 EDTRDNTRadNet reports Q4 EPS 10c, one estimate 10c
Reports Q4 revenue $185.6M, consensus $185.3M.
March 15, 2015
15:27 EDTMDTMedtronic unveils data from high risk study of the CoreValve U.S. pivotal trial
Subscribe for More Information
15:23 EDTMDTMedtronic unveils preclinical outcomes of its novel Drug-Filled Stent
Subscribe for More Information
15:20 EDTMDTMedtronic announces outcomes for its next-generation CoreValve Evolut R System
Medtronic announced initial clinical outcomes for its next-generation CoreValve Evolut R System. At 30-days, the new recapturable, self-expanding valve showed no incidents of all-cause mortality or stroke in a high and extreme risk patient population. Data from the Evolut R Study, which enrolled 60 patients from six centers in the United Kingdom, Australia and New Zealand, were unveiled today at the 64th Annual Scientific Session of the American College of Cardiology. The CoreValve Evolut R System is not approved for commercial use in the United States where it is currently undergoing clinical trials. "Initial clinical experience with the Evolut R system is remarkable and ushers in a new era of TAVR technology that provides increased confidence with recapturability, excellent procedural results, and impressive clinical outcomes," said Ian Meredith, M.D., of Monash Heart - Monash Health, Melbourne, Australia, who is one of the investigators of the study. "The 14 French equivalent delivery system allowed transfemoral access for most patients and the recapturable technology enabled implanters to optimize valve placement for improved annular sealing and reduced conduction disturbances without compromise on mortality or stroke."
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use